Nasal Polyps and Tumours in Dogs: Welfare Guide
Nasal Conditions Overview
The nasal cavity can be affected by several conditions causing chronic nasal discharge, obstruction, and welfare compromise: nasal polyps (benign inflammatory tissue growths); nasal tumours (adenocarcinoma, chondrosarcoma, fibrosarcoma — accounting for 1% of all canine tumours); nasal aspergillosis (fungal infection causing ulcerative rhinitis); and nasal foreign bodies. Distinguishing between these requires careful diagnosis as management differs significantly.
Welfare Impact
Nasal conditions cause significant chronic welfare harm: persistent unilateral or bilateral nasal discharge (serous, mucopurulent, haemorrhagic); nasal deformity (fungal erosion, tumour invasion of nasal bones causing facial swelling); epistaxis (nosebleeds); sneezing; respiratory difficulty; and loss of the sense of smell (severely affecting food motivation and quality of life). Nasal tumours invade locally, causing pain from bone destruction. Dogs typically do not show overt pain signs but behaviour change and reduced activity indicate welfare compromise.
Diagnosis
Diagnostic approach: CT scan (essential — provides detailed anatomy of nasal cavity, extent of disease, and bone involvement); rhinoscopy (direct visualisation and biopsy); nasal flush cytology; serology for Aspergillus; and tissue biopsy (histopathology for definitive diagnosis). Plain radiography is inadequate for detailed nasal assessment; CT is the gold standard and should be the first-line advanced imaging. Thoracic radiography for metastatic screening.
Treatment by Condition
Nasal polyps: surgical debridement (rhinoscopic or surgical removal) provides resolution in some cases; corticosteroids manage underlying inflammation. Nasal aspergillosis: topical clotrimazole infusion (nasal flush or surgical placement via trepanation sites) under general anaesthesia is the most effective treatment; systemic antifungals (itraconazole, voriconazole) as adjuncts. Nasal tumours: radiation therapy is the most effective treatment (median survival 8-12 months with radiation); surgery and chemotherapy have supplementary roles.
Palliative Welfare Management
For nasal tumours, palliative management when radiation is not feasible: NSAIDs provide anti-tumour effect and analgesia (piroxicam has documented efficacy); management of secondary infection; nasal secretion management; and owner support and quality of life assessment. Nasal tumours cause significant welfare compromise in their late stages: blood, appetite loss, facial deformity. Regular quality of life assessment and timely euthanasia decisions are compassionate welfare responsibilities.